These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23040363)

  • 1. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
    Bernstein EJ; Schmidt-Lauber C; Kay J
    Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: clinical picture and treatment.
    Marckmann P; Skov L
    Radiol Clin North Am; 2009 Sep; 47(5):833-40, vi. PubMed ID: 19744598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation.
    Fuah KW; Lim CTS
    BMC Nephrol; 2017 Jul; 18(1):249. PubMed ID: 28738858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadolinium-Induced Fibrosis.
    Todd DJ; Kay J
    Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.
    Larson KN; Gagnon AL; Darling MD; Patterson JW; Cropley TG
    JAMA Dermatol; 2015 Oct; 151(10):1117-20. PubMed ID: 26017458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nephrogenic fibrosing dermatosis: From clinic to microscopy].
    Yoldez H; Ahlem B; Abderrahim E; Faten Z; Soumaya R
    Nephrol Ther; 2018 Feb; 14(1):47-49. PubMed ID: 29239786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late Onset Nephrogenic Systemic Fibrosis in a Patient with Stage 3 Chronic Kidney Disease: a Case Report.
    Lim YJ; Bang J; Ko Y; Seo HM; Jung WY; Yi JH; Han SW; Yu MY
    J Korean Med Sci; 2020 Sep; 35(35):e293. PubMed ID: 32893521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
    Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
    Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
    J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU; Prieto-Rayo JC
    Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage.
    Shankar PR; Davenport MS
    Radiology; 2020 Nov; 297(2):447-448. PubMed ID: 32808890
    [No Abstract]   [Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis: concepts and perspectives.
    Igreja AC; Mesquita Kde C; Cowper SE; Costa IM
    An Bras Dermatol; 2012; 87(4):597-607. PubMed ID: 22892775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadolinium and nephrogenic systemic fibrosis: have we overreacted?
    Penfield JG; Reilly RF
    Semin Dial; 2011; 24(5):480-6. PubMed ID: 21913988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
    Abu-Alfa AK
    Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic Systemic Fibrosis in the Setting of Transient Renal Insufficiency.
    Dinh H; Phan J; Lountzis NI; Purcell SM
    Cutis; 2021 Dec; 108(6):342-344. PubMed ID: 35167789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nephrogenic systemic fibrosis: a rare disease with grave consequences].
    Kielstein JT; Schiffer M
    Internist (Berl); 2010 Jan; 51(1):39-44. PubMed ID: 20033388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.